Murine Hayfever (Sodium Cromoglicate)

Sodium cromoglicate, the active ingredient in Murine Hayfever, is a mast cell stabilizer presented as an ocular formulation for eye use. It treats allergic conjunctivitis and hay‑fever related ocular symptoms in patients with seasonal allergies.

GNH USA supplies Murine Hayfever as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sodium cromoglicate acts on mast cells to reduce ocular allergic responses. It is indicated for several eye‑related allergy conditions.

Allergic conjunctivitis: reduces itching, redness and watery discharge in the eyes. Seasonal allergic rhinoconjunctivitis ocular symptoms: alleviates eye irritation associated with seasonal pollen exposure. Hay‑fever ocular symptoms: stabilises mast cells to prevent histamine‑mediated eye discomfort.

Sodium cromoglicate is generally well tolerated, but ocular administration can be associated with adverse reactions.

Common Side Effects: - Transient eye irritation or burning sensation - Blurred vision shortly after instillation - Mild headache - Taste disturbance when drainage occurs through the nasolacrimal duct - Mild local allergic reaction (redness, swelling) - Temporary discomfort with contact lens wear

Serious or Rare Side Effects: - Severe eye inflammation or keratitis - Anaphylactic reaction (rare but possible) - Sudden loss of vision - Significant ocular edema or ulceration - Persistent severe pain in the eye

Before using Murine Hayfever, consider the following safety measures.

Pregnancy: safety not established; consult a healthcare professional before use. Breastfeeding: unknown safety profile; weigh potential benefits against risks. Concomitant ocular surgery: postpone treatment until the eye has fully healed. Known hypersensitivity: avoid if you have a documented allergy to sodium cromoglicate or any excipients. Storage: Store at room temperature: keep in the original container, protect from light and moisture.

Sodium cromoglicate may interact with other ocular or systemic agents. Review the following interaction categories.

Major Interactions (Avoid): - Concurrent use of ocular antihistamines: may diminish therapeutic effect. - Systemic mast‑cell stabilisers: increased risk of ocular irritation. - Beta‑blocker eye drops: potential additive ocular side‑effects.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: monitor intra‑ocular pressure. - Contact lens wear: may increase drug retention; assess comfort. - Other ocular lubricants or drops: may dilute the dose and affect efficacy.